

Clinical trials of linagliptin low dose

TrialResults-center www.trialresultscenter.org

1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
linagliptin low dose vs linagliptin			
linagliptin 1218.62 <i>ongoing</i> [NCT01012037] n=NA follow-up: 12 weeks	linagliptin low dose 2.5 mg twice daily versus linagliptin medium dose 5 mg once daily	patients with type 2 diabetes mellitus with insufficient glycaemic control with metformin	double-blind Belgium

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

References

linagliptin 1218.62, 0:

ongoing trial NCT01012037

Entry terms: linagliptin, Linagliptin, Tradjenta, BI 1356, BI1356, BI-1356,